HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 72-79

  Huang, Xiaoping ^a   Wang, Shuiliang ^a   Lee, Choon Kee ^a   Yang, XiaoHe ^b   Liu, Bolin ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; ErbB receptor; HDAC; SNDX 275; Trastuzumab resistance

Indexed keywords

CASPASE 3; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOPRECIPITATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TUMOR CELLS, CULTURED;

EID: 79957514394     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.019     Document Type: Article

References (49)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
2. Thor A.D., Schwartz L.H., Koerner F.C., Edgerton S.M., Skates S.J., Yin S., McKenzie S.J., Panicali D.L., Marks P.J., Fingert H.J., Wood W.C. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 1989, 49:7147-7152.
3. Nahta R., Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643.
4. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
5. Hudis C.A. Trastuzumab - mechanism of action and use in clinical practice. New. Engl. J. Med. 2007, 357:39-51.
6. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New. Engl. J. Med. 2001, 344:783-792.
7. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
8. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007, 18:977-984.
9. Cress W.D., Seto E. Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 2000, 184:1-16.
10. Mahlknecht U., Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 2000, 6:623-644.
11. Mottet D., Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin. Exp. Metastasis 2008, 25:183-189.
12. Yang X.J., Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26:5310-5318.
13. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discovery 2006, 5:769-784.
14. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
15. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
16. Ma X., Ezzeldin H.H., Diasio R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69:1911-1934.
17. Tan J., Cang S., Ma Y., Petrillo R.L., Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 2010, 3:5.
18. Lee B.I., Park S.H., Kim J.W., Sausville E.A., Kim H.T., Nakanishi O., Trepel J.B., Kim S.J. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res. 2001, 61:931-934.
19. Park S.H., Lee S.R., Kim B.C., Cho E.A., Patel S.P., Kang H.B., Sausville E.A., Nakanishi O., Trepel J.B., Lee B.I., Kim S.J. Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J. Biol. Chem. 2002, 277:5168-5174.
20. Singh T.R., Shankar S., Srivastava R.K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005, 24:4609-4623.
21. Xu J., Zhou J.Y., Wei W.Z., Philipsen S., Wu G.S. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008, 68:6718-6726.
22. Zhou Q., Agoston A.T., Atadja P., Nelson W.G., Davidson N.E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol. Cancer Res. 2008, 6:873-883.
23. Huang X., Gao L., Wang S., Lee C.K., Ordentlich P., Liu B. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res. 2009, 69:8403-8411.
24. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int. J. Cancer 2003, 106:758-765.
25. deFazio A., Chiew Y.E., Sini R.L., Janes P.W., Sutherland R.L. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer 2000, 87:487-498.
26. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
27. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., van de Vijver M.J., Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
28. Huang X., Gao L., Wang S., McManaman J.L., Thor A.D., Yang X., Esteva F.J., Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010, 70:1204-1214.
29. Wang S., Huang X., Lee C.K., Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010, 29:4225-4236.
30. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1:194-202.
31. Gore L., Rothenberg M.L., O'Bryant C.L., Schultz M.K., Sandler A.B., Coffin D., McCoy C., Schott A., Scholz C., Eckhardt S.G. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 2008, 14:4517-4525.
32. Kummar S., Gutierrez M., Gardner E.R., Donovan E., Hwang K., Chung E.J., Lee M.J., Maynard K., Kalnitskiy M., Chen A., Melillo G., Ryan Q.C., Conley B., Figg W.D., Trepel J.B., Zwiebel J., Doroshow J.H., Murgo A.J. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res. 2007, 13:5411-5417.
33. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., Sausville E.A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23:3912-3922.
34. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., 3rd, Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 100:8933-8938.
35. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp. Cell Res. 2003, 284:54-65.
36. Jin Q., Esteva F.J. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13:485-498.
37. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S.D., Stein S., Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New. Engl. J. Med. 2006, 355:2733-2743.
38. Chen F.L., Xia W., Spector N.L. Acquired resistance to small molecule erbB2 tyrosine kinase inhibitors. Clin. Cancer Res. 2008, 14:6730-6734.
39. Vazquez-Martin A., Oliveras-Ferraros C., Del Barco S., Martin-Castillo B., Menendez J.A. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R). Clin. Transl. Oncol. 2009, 11:455-459.
40. Cameron D.A., Stein S. Drug insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. Nat. Clin. Pract. Oncol. 2008, 5:512-520.
41. McArthur H. An overview of HER-targeted therapy with lapatinib in breast cancer. Adv. Ther. 2009, 26:263-271.
42. Medina P.J., Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 2008, 30:1426-1447.
43. Ryan Q., Ibrahim A., Cohen M.H., Johnson J., Ko C.W., Sridhara R., Justice R., Pazdur R. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008, 13:1114-1119.
44. Xia W., Husain I., Liu L., Bacus S., Saini S., Spohn J., Pry K., Westlund R., Stein S.H., Spector N.L. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in erbB2-overexpressing breast cancers. Cancer Res. 2007, 67:1170-1175.
45. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., Beijersbergen R.L., Valero V., Seoane J., Bernards R., Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008, 68:9221-9230.
46. LaFortune T.A., Ordentlich P., Zhang D., Hortobagyi G.N., Cristofanilli M., Uneno N.T. Synergistic effect of lapatinib and the class I HADC inhibitor SNDX-275 in breast cancer. Cancer Res. 2009, 69(Suppl.):691S.
47. Kurokawa H., Arteaga C.L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin. Cancer Res. 2003, 9:511S-515S.
48. Knuefermann C., Lu Y., Liu B., Jin W., Liang K., Wu L., Schmidt M., Mills G.B., Mendelsohn J., Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212.
49. Liu B., Ordonez-Ercan D., Fan Z., Edgerton S.M., Yang X., Thor A.D. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int. J. Cancer 2007, 120:1874-1882.